# US 5,858,683 A · Methods and compositions for the detection of cervical cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,683 A
- Document ID: US5858683A
- Status: Granted
- Kind: A
- Application number: 08/705,660
- Filed: 1996-08-30
- Granted: 1999-01-12
- Earliest claimed: 1996-08-30
- Assignees: Matritech, Inc.
- Inventors: Susan K. Keesee; Robert Obar; Ying-Jye Wu
- Web page: https://patentgrep.com/patent/US5858683A

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- G01N 33/57595: {involving intracellular compounds}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6851: {Methods of protein analysis involving laser desorption ionisation mass spectrometry}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a wide range of methods and compositions for detecting and treating cervical cancer in an individual. Specifically, the invention provides target cervical cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of cervical cancer. The target cervical cancer-associated protein, may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of cervical cancer in an individual. In addition, the invention provides methods utilizing the cervical cancer-associated proteins either as targets for treating cervical cancer or as indicators for monitoring of the efficacy of such a treatment.

## Claims

### Claim 1

A method of detecting cervical cancer in a human, the method comprising:
detecting in a sample isolated from said human the presence of a protein comprising an amino acid sequence selected from the group of sequences consisting of SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; and SEQ ID NO:26, the presence of said protein being indicative of cervical cancer in said human.

### Claim 2 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:19.

### Claim 3 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:20.

### Claim 4 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:21.

### Claim 5 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:22.

### Claim 6 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:23.

### Claim 7 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:24.

### Claim 8 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:25.

### Claim 9 (depends on 1)

The method of claim 1, wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:26.

### Claim 10 (depends on 1)

The method of claim 1, wherein said sample is a tissue or body fluid sample.

### Claim 11 (depends on 1)

The method of claim 1, wherein said sample is a biopsy sample.

### Claim 12 (depends on 1)

The method of claim 1, wherein said sample is a cervical cell sample.

### Claim 13 (depends on 1)

The method of claim 1, wherein said sample is a Papanicolaou smear.

### Claim 14

A method of detecting cervical cancer in a human, the method comprising the steps of:
(a) contacting a sample derived from said human with a binding moiety that binds specifically to a cervical cancer-associated protein to produce a binding moiety-cervical cancer-associated protein complex, wherein said binding moiety is selected from the group consisting of an antibody, an antibody fragment and a biosynthetic antibody binding site, and wherein said binding moiety binds specifically to a protein comprising the amino acid sequence set forth in SEQ ID NO:26; and
(b) detecting the presence of said complex, the presence of said complex being indicative of the presence of cervical cancer in said human.

### Claim 15 (depends on 14)

The method of claim 14, wherein said cervical cancer-associated protein is further characterized as being detectable at a higher level in a human cervical cancer cell than in a normal human cervical cell, as determined by two dimensional gel electrophoresis.

### Claim 16 (depends on 14)

The method of claim 14, wherein said sample is a tissue or body fluid sample.

### Claim 17 (depends on 14)

The method of claim 14, wherein said sample is a biopsy sample.

### Claim 18 (depends on 14)

The method of claim 14, wherein said sample is a Papanicolaou smear.

### Claim 19 (depends on 14)

The method of claim 14, wherein said sample is a cervical cell sample.

### Claim 20 (depends on 14)

The method of claim 14, wherein said binding moiety is an antibody.

### Claim 21 (depends on 20)

The method of claim 20, wherein said antibody is a monoclonal antibody.

### Claim 22 (depends on 20)

The method of claim 20, wherein said antibody is labeled with a detectable moiety.

### Claim 23 (depends on 21)

The method of claim 21, wherein said monoclonal antibody is labeled with a detectable moiety.
